Preclinical and clinical evidence of NAD + precursors in health, disease, and ageing.

Autor: Reiten OK; Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478, Lørenskog, Norway., Wilvang MA; Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478, Lørenskog, Norway., Mitchell SJ; Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerland., Hu Z; School of Pharmaceutical Sciences, Tsinghua-Peking Joint Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University, Beijing, 100084, China., Fang EF; Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478, Lørenskog, Norway; The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway. Electronic address: e.f.fang@medisin.uio.no.
Jazyk: angličtina
Zdroj: Mechanisms of ageing and development [Mech Ageing Dev] 2021 Oct; Vol. 199, pp. 111567. Date of Electronic Publication: 2021 Sep 10.
DOI: 10.1016/j.mad.2021.111567
Abstrakt: NAD + is a fundamental molecule in human life and health as it participates in energy metabolism, cell signalling, mitochondrial homeostasis, and in dictating cell survival or death. Emerging evidence from preclinical and human studies indicates an age-dependent reduction of cellular NAD + , possibly due to reduced synthesis and increased consumption. In preclinical models, NAD + repletion extends healthspan and / or lifespan and mitigates several conditions, such as premature ageing diseases and neurodegenerative diseases. These findings suggest that NAD + replenishment through NAD + precursors has great potential as a therapeutic target for ageing and age-predisposed diseases, such as Alzheimer's disease. Here, we provide an updated review on the biological activity, safety, and possible side effects of NAD + precursors in preclinical and clinical studies. Major NAD + precursors focused on by this review are nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and the new discovered dihydronicotinamide riboside (NRH). In summary, NAD + precursors have an exciting therapeutic potential for ageing, metabolic and neurodegenerative diseases.
(Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: